A citation-based method for searching scientific literature

Kenji Rowel Q Lim, Rika Maruyama, Toshifumi Yokota. Drug Des Devel Ther 2017
Times Cited: 177







List of co-cited articles
1117 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Golodirsen: First Approval.
Young-A Heo. Drugs 2020
62
30

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.
Catherine L Bladen, David Salgado, Soledad Monges, Maria E Foncuberta, Kyriaki Kekou, Konstantina Kosma, Hugh Dawkins, Leanne Lamont, Anna J Roy, Teodora Chamova,[...]. Hum Mutat 2015
284
17


Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Merrill D Benson, Márcia Waddington-Cruz, John L Berk, Michael Polydefkis, Peter J Dyck, Annabel K Wang, Violaine Planté-Bordeneuve, Fabio A Barroso, Giampaolo Merlini, Laura Obici,[...]. N Engl J Med 2018
485
14

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
Jerry R Mendell, Nathalie Goemans, Linda P Lowes, Lindsay N Alfano, Katherine Berry, James Shao, Edward M Kaye, Eugenio Mercuri. Ann Neurol 2016
274
13


Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.
Jinkuk Kim, Chunguang Hu, Christelle Moufawad El Achkar, Lauren E Black, Julie Douville, Austin Larson, Mary K Pendergast, Sara F Goldkind, Eunjung A Lee, Ashley Kuniholm,[...]. N Engl J Med 2019
155
13

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Eugenio Mercuri, Basil T Darras, Claudia A Chiriboga, John W Day, Craig Campbell, Anne M Connolly, Susan T Iannaccone, Janbernd Kirschner, Nancy L Kuntz, Kayoko Saito,[...]. N Engl J Med 2018
501
12

The delivery of therapeutic oligonucleotides.
Rudolph L Juliano. Nucleic Acids Res 2016
400
12

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, Chih-Chao Yang, Mitsuharu Ueda, Arnt V Kristen, Ivailo Tournev, Hartmut H Schmidt, Teresa Coelho, John L Berk,[...]. N Engl J Med 2018
857
12

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Richard S Finkel, Eugenio Mercuri, Basil T Darras, Anne M Connolly, Nancy L Kuntz, Janbernd Kirschner, Claudia A Chiriboga, Kayoko Saito, Laurent Servais, Eduardo Tizzano,[...]. N Engl J Med 2017
749
11

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Sebahattin Cirak, Virginia Arechavala-Gomeza, Michela Guglieri, Lucy Feng, Silvia Torelli, Karen Anthony, Stephen Abbs, Maria Elena Garralda, John Bourke, Dominic J Wells,[...]. Lancet 2011
593
11


An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.
A P Monaco, C J Bertelson, S Liechti-Gallati, H Moser, L M Kunkel. Genomics 1988
903
10

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.
Katharine Bushby, Richard Finkel, David J Birnkrant, Laura E Case, Paula R Clemens, Linda Cripe, Ajay Kaul, Kathi Kinnett, Craig McDonald, Shree Pandya,[...]. Lancet Neurol 2010
10

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
Richard S Geary, Daniel Norris, Rosie Yu, C Frank Bennett. Adv Drug Deliv Rev 2015
380
10

FDA-Approved Oligonucleotide Therapies in 2017.
Cy A Stein, Daniela Castanotto. Mol Ther 2017
340
10


Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
Diane E Frank, Frederick J Schnell, Cody Akana, Saleh H El-Husayni, Cody A Desjardins, Jennifer Morgan, Jay S Charleston, Valentina Sardone, Joana Domingos, George Dickson,[...]. Neurology 2020
66
15

The chemical evolution of oligonucleotide therapies of clinical utility.
Anastasia Khvorova, Jonathan K Watts. Nat Biotechnol 2017
386
9

Cellular uptake and trafficking of antisense oligonucleotides.
Stanley T Crooke, Shiyu Wang, Timothy A Vickers, Wen Shen, Xue-Hai Liang. Nat Biotechnol 2017
213
9

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
A Fire, S Xu, M K Montgomery, S A Kostas, S E Driver, C C Mello. Nature 1998
9

Ataluren treatment of patients with nonsense mutation dystrophinopathy.
Katharine Bushby, Richard Finkel, Brenda Wong, Richard Barohn, Craig Campbell, Giacomo P Comi, Anne M Connolly, John W Day, Kevin M Flanigan, Nathalie Goemans,[...]. Muscle Nerve 2014
235
9

Eteplirsen for the treatment of Duchenne muscular dystrophy.
Jerry R Mendell, Louise R Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird, Linda P Lowes, Lindsay Alfano, Ann Maria Gomez, Sarah Lewis, Janaiah Kota,[...]. Ann Neurol 2013
428
9

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig M McDonald, Craig Campbell, Ricardo Erazo Torricelli, Richard S Finkel, Kevin M Flanigan, Nathalie Goemans, Peter Heydemann, Anna Kaminska, Janbernd Kirschner, Francesco Muntoni,[...]. Lancet 2017
187
9

Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs.
Hongjiang Wu, Walt F Lima, Hong Zhang, Amy Fan, Hong Sun, Stanley T Crooke. J Biol Chem 2004
185
9

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
Christopher E Nelson, Chady H Hakim, David G Ousterout, Pratiksha I Thakore, Eirik A Moreb, Ruth M Castellanos Rivera, Sarina Madhavan, Xiufang Pan, F Ann Ran, Winston X Yan,[...]. Science 2016
637
9

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Thazha P Prakash, Mark J Graham, Jinghua Yu, Rick Carty, Audrey Low, Alfred Chappell, Karsten Schmidt, Chenguang Zhao, Mariam Aghajan, Heather F Murray,[...]. Nucleic Acids Res 2014
273
9

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges.
Yusuke Echigoya, Kenji Rowel Q Lim, Akinori Nakamura, Toshifumi Yokota. J Pers Med 2018
27
33

Splice-switching antisense oligonucleotides as therapeutic drugs.
Mallory A Havens, Michelle L Hastings. Nucleic Acids Res 2016
191
9

Givosiran: First Approval.
Lesley J Scott. Drugs 2020
90
10

Morpholino antisense oligomers: design, preparation, and properties.
J Summerton, D Weller. Antisense Nucleic Acid Drug Dev 1997
722
8

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Martin Jinek, Krzysztof Chylinski, Ines Fonfara, Michael Hauer, Jennifer A Doudna, Emmanuelle Charpentier. Science 2012
8


Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
Yusuke Echigoya, Akinori Nakamura, Tetsuya Nagata, Nobuyuki Urasawa, Kenji Rowel Q Lim, Nhu Trieu, Dharminder Panesar, Mutsuki Kuraoka, Hong M Moulton, Takashi Saito,[...]. Proc Natl Acad Sci U S A 2017
57
14

The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.
P Sicinski, Y Geng, A S Ryder-Cook, E A Barnard, M G Darlison, P J Barnard. Science 1989
983
8

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Annemieke Aartsma-Rus, Ivo Fokkema, Jan Verschuuren, Ieke Ginjaar, Judith van Deutekom, Gert-Jan van Ommen, Johan T den Dunnen. Hum Mutat 2009
342
8





Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.
Joe W McGreevy, Chady H Hakim, Mark A McIntosh, Dongsheng Duan. Dis Model Mech 2015
221
8

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy.
Leonela Amoasii, John C W Hildyard, Hui Li, Efrain Sanchez-Ortiz, Alex Mireault, Daniel Caballero, Rachel Harron, Thaleia-Rengina Stathopoulou, Claire Massey, John M Shelton,[...]. Science 2018
213
8

Dystrophin and mutations: one gene, several proteins, multiple phenotypes.
Francesco Muntoni, Silvia Torelli, Alessandra Ferlini. Lancet Neurol 2003
580
8


Viltolarsen for the treatment of Duchenne muscular dystrophy.
R R Roshmi, T Yokota. Drugs Today (Barc) 2019
19
42

Evidence-based path to newborn screening for Duchenne muscular dystrophy.
Jerry R Mendell, Chris Shilling, Nancy D Leslie, Kevin M Flanigan, Roula al-Dahhak, Julie Gastier-Foster, Kelley Kneile, Diane M Dunn, Brett Duval, Alexander Aoyagi,[...]. Ann Neurol 2012
431
7


Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Raul D Santos, Dirk J Blom, A David Marais, Min-Ji Charng, William C Cromwell, Robin H Lachmann, Daniel Gaudet, Ju L Tan, Scott Chasan-Taber,[...]. Lancet 2010
602
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.